Literature DB >> 2714860

Four-year experience with a recombinant hepatitis B vaccine.

W Jilg1, M Schmidt, F Deinhardt.   

Abstract

Three hundred and forty-three healthy adults were vaccinated with five different lots of recombinant hepatitis B vaccine. Three hundred and forty (99.1%) individuals produced antibodies against hepatitis B surface antigen (anti-HBs). Peak anti-HBs concentrations were significantly higher in females and younger individuals. All anti-HBs positive individuals developed antibodies to the common determinant "a" of HBsAg. The vaccine was well tolerated, without severe side reactions. Persistence of anti-HBs was followed in 130 individuals for 3, and in 15 for 4 years after the first vaccination of these two groups. 21.7% and 32.3%, respectively, no longer had protective levels of anti-HBs after this time. The persistence of anti-HBs was dependent on peak anti-HBs levels, with consistent kinetics of anti-HBs decline. Revaccination of individuals whose specific antibody levels had fallen below 10 IU/l led to a prompt anti-HBs response. Comparison with individuals vaccinated with plasma-derived hepatitis B vaccine revealed no substantial differences between the two vaccines.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2714860     DOI： 10.1007/BF01646879

Source DB:  PubMed          Journal:  Infection        ISSN： 0300-8126            Impact factor:   3.553


  25 in total

1.  Is booster injection with hepatitis B vaccine necessary in healthy responders? A study of the immune response.

Authors:  P J Wismans; J van Hattum; G C Mudde; H J Endeman; J Poel; G C de Gast
Journal:  J Hepatol       Date:  1989-03       Impact factor: 25.083

2.  Immune response to hepatitis B revaccination.

Authors:  W Jilg; M Schmidt; F Deinhardt
Journal:  J Med Virol       Date:  1988-04       Impact factor: 2.327

3.  Immune response after vaccination with recombinant hepatitis B vaccine as compared to that after plasma-derived vaccine.

Authors:  R A Heijtink; J Kruining; M Bakker; S W Schalm
Journal:  Antiviral Res       Date:  1985       Impact factor: 5.970

4.  Hepatitis B vaccination: how long does protection last?

Authors:  W Jilg; M Schmidt; F Deinhardt; R Zachoval
Journal:  Lancet       Date:  1984-08-25       Impact factor: 79.321

5.  Immunogenicity of recombinant yeast hepatitis B vaccine.

Authors:  M Davidson; S Krugman
Journal:  Lancet       Date:  1985-01-12       Impact factor: 79.321

6.  Subtyping of hepatitis B surface antigen and antibody by radioimmunoassay.

Authors:  J H Hoofnagle; R J Gerety; L A Smallwood; L F Barker
Journal:  Gastroenterology       Date:  1977-02       Impact factor: 22.682

7.  The immune response of healthy adults to a reduced dose of hepatitis B vaccine.

Authors:  W Szmuness; C E Stevens; E J Harley; E A Zang; P E Taylor; H J Alter
Journal:  J Med Virol       Date:  1981       Impact factor: 2.327

8.  Human hepatitis B vaccine from recombinant yeast.

Authors:  W J McAleer; E B Buynak; R Z Maigetter; D E Wampler; W J Miller; M R Hilleman
Journal:  Nature       Date:  1984 Jan 12-18       Impact factor: 49.962

9.  Hepatitis B vaccine: immune responses in haemodialysis patients.

Authors:  C E Stevens; W Szmuness; A I Goodman; S A Weseley; M Fotino
Journal:  Lancet       Date:  1980-12-06       Impact factor: 79.321

10.  A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report.

Authors:  W Szmuness; C E Stevens; E A Zang; E J Harley; A Kellner
Journal:  Hepatology       Date:  1981 Sep-Oct       Impact factor: 17.425
View more
  10 in total

1.  Influence of vaccination schedules and host factors on antibody response following hepatitis B vaccination.

Authors:  G Hess; V Hingst; J Cseke; H L Bock; R Clemens
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-04       Impact factor: 3.267

2.  Hepatitis B immune status in adolescents vaccinated during infancy: A retrospective cohort study from a pediatric practice in Germany.

Authors:  Carrie L Anderson; Cornelius Remschmidt; Frank-Peter Drobnitzky; Gerhard Falkenhorst; Ruth Zimmermann; Ole Wichmann; Thomas Harder
Journal:  Hum Vaccin Immunother       Date:  2016-03-03       Impact factor: 3.452

3.  Response to a booster dose 18 months after a low anti-HBs response (10-99 IU/l) to three doses of intradermally or intramuscularly administered recombinant hepatitis B vaccine.

Authors:  J Struve; B Aronsson; B Frenning; M Forsgren; O Weiland
Journal:  Infection       Date:  1995 Jan-Feb       Impact factor: 3.553

Review 4.  Prevalence of National Responsiveness to HBV Vaccine After 22 Years of Iranian Expanded Program on Immunization (EPI): A Systematic Review and Meta-Analysis Study.

Authors:  Reza Rezaee; Bahman Aghcheli; Vahdat Poortahmasebi; Mostafa Qorbani; Seyed Moayed Alavian; Seyed Mohammad Jazayeri
Journal:  Hepat Mon       Date:  2015-04-25       Impact factor: 0.660

Review 5.  Insights into induction of the immune response by the hepatitis B vaccine.

Authors:  Federico Alejandro Di Lello; Alfredo Pedro Martínez; Diego Martín Flichman
Journal:  World J Gastroenterol       Date:  2022-08-21       Impact factor: 5.374

Review 6.  Chronic Viral Hepatitis in Elite Athletes: Approaches to Risk Assessment, Prevention and Management.

Authors:  Lung-Yi Mak; Ian Beasley; Patrick T F Kennedy
Journal:  Sports Med Open       Date:  2022-10-04

7.  Randomized controlled trial of RTS,S/AS02D and RTS,S/AS01E malaria candidate vaccines given according to different schedules in Ghanaian children.

Authors:  Seth Owusu-Agyei; Daniel Ansong; Kwaku Asante; Sandra Kwarteng Owusu; Ruth Owusu; Naana Ayiwa Wireko Brobby; David Dosoo; Alex Osei Akoto; Kingsley Osei-Kwakye; Emmanuel Asafo Adjei; Kwadwo Owusu Boahen; Justice Sylverken; George Adjei; David Sambian; Stephen Apanga; Kingsley Kayan; Johan Vekemans; Opokua Ofori-Anyinam; Amanda Leach; Marc Lievens; Marie-Ange Demoitie; Marie-Claude Dubois; Joe Cohen; W Ripley Ballou; Barbara Savarese; Daniel Chandramohan; John Owusu Gyapong; Paul Milligan; Sampson Antwi; Tsiri Agbenyega; Brian Greenwood; Jennifer Evans
Journal:  PLoS One       Date:  2009-10-02       Impact factor: 3.240

Review 8.  The major histocompatibility complex: the value of extended haplotypes in the analysis of associated immune diseases and disorders.

Authors:  M S Kruskall
Journal:  Yale J Biol Med       Date:  1990 Sep-Oct

9.  Long-term immunogenicity and immune memory response to the hepatitis B antigen in the RTS,S/AS01E malaria vaccine in African children: a randomized trial.

Authors:  Innocent Valéa; Samuel Adjei; Effua Usuf; Ousmane Traore; Daniel Ansong; Halidou Tinto; Harry Owusu Boateng; Athanase Mwinessobaonfou Some; Patrick Buabeng; Johan Vekemans; Amos Kotey; Pascale Vandoolaeghe; Mark Cullinane; Magali Traskine; Florence Ouedraogo; David Sambian; Marc Lievens; Marc Christian Tahita; Erik Jongert; Palpouguini Lompo; Ali Idriss; Dorota Borys; Sayouba Ouedraogo; Frank Prempeh; Lode Schuerman; Hermann Sorgho; Tsiri Agbenyega
Journal:  Hum Vaccin Immunother       Date:  2020-01-17       Impact factor: 3.452

10.  [Hepatitis B virus infection and vaccine-induced immunity: the role of sociodemographic determinants : Results of the study "German Health Interview and Examination Survey for Adults" (DEGS1, 2008-2011)].

Authors:  Annika Brodzinski; Angela Neumeyer-Gromen; Sandra Dudareva; Ruth Zimmermann; Ute Latza; Viviane Bremer; Christina Poethko-Müller
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2021-12-27       Impact factor: 1.513
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.